Research in contextEvidence before this studyEpilepsy is a major public health problem in Sub-Saharan Africa, where wide treatment gaps result in high comorbidity and mortality. Previous studies have suggested that financial limitations to acquire antiepileptic drugs are the main reasons for the poor treatment adherence by persons with epilepsy. We searched PubMed for studies reporting the economic burden of epilepsy in Africa and realized that no data is available in the Democratic Republic of Congo, where epilepsy prevalence is very high especially in onchocerciasis-endemic areas with inadequate control measures.Added value of this studyIn this study, we analysed the different costs relating to epilepsy and reported for the first time the economic burden of epilepsy for families and communities in the Democratic Republic of Congo. Our findings reveal that the cost of managing a person with epilepsy in rural Democratic Republic of Congo amounts to almost half of the household income of our study participants. Additionally, persons with epilepsy spend the greater part of their limited resources on traditional medicine. Consequently, they are unable to afford proper medical treatment and frequently develop complications which further increase cost. We also show the economic benefits of preventing epilepsy and providing recommended care to affected persons.Implications of all available evidenceThe economic burden of epilepsy in rural settings can be reduced by ensuring continuous availability of cheap antiepileptic drugs. In villages which are endemic for onchocerciasis, reinforcing onchocerciasis elimination measures may prevent new cases of epilepsy in children, thereby curbing related costs.Alt-text: Unlabelled Box

1. Background {#s0025}
=============

Epilepsy remains a major public health concern around the world and especially in developing countries where 80% of the affected 50 million persons currently live. The situation is even more deplorable as 75% of persons with epilepsy (PWE) in resource-poor settings do not receive treatment [@bb0005]. One of the main reasons for this wide epilepsy treatment gap is the limited finances to afford continuous treatment by affected families [@bb0010], [@bb0015]. The financial burden is exacerbated by the absence of health insurance in most developing countries, resulting in most expenditures being out-of-pocket [@bb0020]. A good understanding of the economic costs associated with epilepsy care could help stakeholders to address the root causes of the wide treatment gap, thus ensuring better health outcomes for the PWE. However, data on epilepsy cost is relatively scarce in developing countries, as only a few studies have been realized in that domain [@bb0020], [@bb0025], [@bb0030], [@bb0035] and none in the Democratic Republic of Congo.

The components of a cost-of-illness analysis can be categorized into direct costs (cost of medical treatment, paraclinical workups and other non-medical expenditures directly related to patient management such as transportation cost to the hospital or home care expenses); indirect costs (due to lost productivity and/or earnings because of the illness); and intangible costs (related to the emotional and social impacts of the illness on the economy) [@bb0020]. Obtaining data on the economic cost of epilepsy can be a daunting task because PWE have different treatment options, seizure severity and accessibility to health facility, all of which can influence expenditure and losses [@bb0040]. Moreover, the total economic cost of any condition cannot be fully grasped because of the near impossibility of estimating intangible costs in monetary terms. Notwithstanding, evaluating direct cost alone and addressing its causes can potentially reduce indirect cost (due to increased productivity) and intangible cost (due to improved quality of life) [@bb0020]. Therefore, assessing health-related expenses will go a long way to reduce cost by implementing optimal solutions based on evidence [@bb0045]. This holds true for epilepsy which is a chronic, stigmatizing condition for which entire families often lose money, labour and time because of a single PWE. This study throws some light on the cost of managing PWE in rural Ituri as well as the financial burden for the family and community, so as to make recommendations for better outcomes at the least cost.

2. Methods {#s0030}
==========

2.1. Study Site {#s0035}
---------------

This study was carried out in the Ituri province of the Democratic Republic of Congo (DRC), more precisely in the Logo Health Zone in the villages of Draju and Kanga. The total population in this health zone at the time of the study was 255,485 [@bb0050]. Although this area is hyperendemic for onchocerciasis, some villages had never received ivermectin for onchocerciasis control [@bb0055]. Previous surveys have established epidemiological evidence suggesting that areas with high onchocerciasis transmission are prone to increased prevalence of epilepsy, in what is known as onchocerciasis-associated epilepsy (OAE) [@bb0060]. A recent community-based study by our research team showed an epilepsy prevalence of 4.6% in the villages where this study was performed [@bb0065]. Most of the population was involved in subsistence farming and living standards were very low as a result of poverty. Consequently, many PWE were not properly treated. Due to the proximity with the Ugandan border, the main currency used in this part of the country was the Ugandan shilling. The American dollar (USD) was also accepted by some farmers and petty traders.

The Logo health zone had one reference hospital with five doctors, and 26 health centres headed by nurses. There was no neurologist, no electroencephalogram (EEG) nor imaging facilities (CT scan, Magnetic Resonance Imaging) for adequate investigation of epilepsy. Also, there was no health insurance to cover medical expenses. Drug supply followed a regional distribution network established by the government. Antiepileptic drugs (AEDs) were supplied to the reference hospital irregularly. Each PWE was expected to pay a monthly sum of 7000 Ugandan shillings (about 2 USD) for a medical consultation and AED refill at the reference hospital; however, these AEDs did not reach the local health centres. As a result, there was a proliferation of private drug vendors who retailed AEDs locally at arbitrarily high costs, up to 20 USD in some cases [@bb0070]. Recently, our research team at the Global Health Institute (University of Antwerp, Belgium) partnered with the organization Malteser International to continuously provide free AEDs for all PWE in the Logo Health Zone [@bb0065]. There were several traditional healers in the villages as well.

2.2. Definition of Terms and Data Collection {#s0040}
--------------------------------------------

Epilepsy was defined as the occurrence of at least two unprovoked seizures separated by 24 h or more [@bb0075]. Based on this definition, we recruited PWE and their families to participate in an epilepsy study by our research team in the Draju and Kanga health centres of the Logo Health Zone during the month of November 2017. A questionnaire to investigate the financial burden of epilepsy on the affected families was elaborated and pre-tested on the local population (see Supplementary appendix 1). Villages were sensitized by community health workers and PWE reported to the health centres with at least one caretaker. Potential participants were informed and clarified about the study in the local *Alur* language by one of the investigators (DWR). After giving their signed informed consent at a registration desk, participants were sent to a consultation room to be clerked by a physician who doubled as investigator in charge of administering the questionnaire. Local community health workers served as interpreters to communicate the questions in the local *Alur* language. Questions were asked about their monthly expenditure on AEDs, hospital consultations and follow-up for epilepsy, paraclinical examinations, transport for epilepsy-related purposes (AED purchase or coming to the hospital for follow-up), as well as expenses on traditional healers; all these constituted epilepsy-related direct cost. Indirect cost was evaluated by asking for the number of days lost by the PWE due to seizures, and the number of days lost by a caretaker when watching over the PWE. Finally, the average monetary revenue per month was noted for each investigated household.

2.3. Estimation of Costs in Monetary Terms {#s0045}
------------------------------------------

Direct costs such as consultation fee, paraclinical exams, hospitalization fee and price of AED were obtained from the PWE and their families. Given that the major means of transport in such rural settings was by motor bikes, the cost of transport for epilepsy-related issues was estimated based on the amount of money paid by the PWE and/or the caretaker to a transporting motor bike driver. Participants or families who owned motor bikes by themselves were asked for the cost of fuel when running epilepsy-related errands. Some PWE consulted traditional healers on an irregular basis; for each PWE who did, we asked what it costs them every year (in cash and in kind), under normal circumstances, to visit the traditional healer because of epilepsy. The average traditional medicine expenditure for a normal year was divided by 12 to obtain monthly costs. To quantify in-kind payments, we averaged the cost of a chicken to be worth 10,000 Ugandan shillings, and a goat/sheep to cost 60,000 Ugandan shillings based on local prices at the time of the study. The total monthly income of a household was taken as the total amount of money all household members can cumulatively generate on average from their respective activities every month, which in most cases was the sales of agricultural products.

For indirect costs, we attributed a monetary value to the number of days of work lost by the PWE and their caretakers because of epilepsy-related causes. This was done by expressing these lost days as multiples of the Gross Domestic Product (GDP) per capita per day as previously described by other authors [@bb0025].

Direct, indirect and total costs were converted to the American dollar (USD) using the exchange rate of 1 USD = 3600 Ugandan shillings which was routinely applicable at our study site in November 2017. Comparison of epilepsy cost across countries and years was done by converting all values to 2016 international dollars. We proceeded by first inflating all values in local currency from the study year to 2016 values using the Consumer Price Index, and thereafter converting the local currency to 2016 international dollars by means of the power purchasing parity (PPP) for private consumption. All indicators were obtained from the World Bank official website (<https://data.worldbank.org/indicator/>).

2.4. Data Analysis {#s0050}
------------------

The collected information was entered into Microsoft Excel 2016 spreadsheets (Microsoft Corporation, USA) and analysed using GraphPad Prism version 5. We constructed a Tornado diagram using RStudio Version 0.99.491. For each epilepsy-related expenditure, only PWE who spent in that particular aspect were included in the analysis. For instance, the mean cost of AEDs was calculated using only the sub-population of PWE who reported spending on AED purchase. Categorical data was presented as percentages, while continuous cost data was expressed as mean ± standard deviation (SD) [@bb0080]. During statistical testing, any p-value \< 0.05 was considered to be significant.

2.5. Ethical Considerations {#s0055}
---------------------------

All participants gave an informed consent to answer epilepsy cost-related questions. For minors, consent was given by the parent or legal guardian who also provided the answers to the questions. All data was treated confidentially. In addition, a community-based epilepsy treatment programme was established to care for PWE in the study villages.

3. Results {#s0060}
==========

3.1. Socio-demographic Characteristics of Study Participants {#s0065}
------------------------------------------------------------

A total of 258 PWE were recruited into the study, with 124 (48.1%) being female. The median age was 20 years (IQR: 15--29), and the median duration of epilepsy was 8 years (IQR: 3--14). Of the 258 PWE, 201 (77.9%) were farmers. Twelve (4.9%) of the 244 households had two or more PWE.

3.2. Direct Cost of Epilepsy {#s0070}
----------------------------

The mean direct cost of epilepsy, after weighting with the proportion of PWE spending on the respective items, was 10.1 USD per PWE per month ([Table 1](#t0005){ref-type="table"}). Traditional medicine cost was most prominent, accounting for 68.2% of the mean direct cost ([Fig. 1](#f0005){ref-type="fig"}). Sixty-five percent of traditional medicine cost was paid in cash, while 35% was supplied in kind. However, these proportions were estimated based on interviews of only 68 PWE, because some investigators reported the total traditional medicine cost without distinguishing cash and kind payments. Nothing was spent on paraclinical investigations for epilepsy because they were unavailable at the study site. The weighted median direct cost of epilepsy was 3.8 USD per month.Table 1Monthly direct costs of epilepsy.Table 1ItemNumber of PWE spending on this item (%)Cost in USD: mean (SD)Weighted mean direct cost (USD)Proportion of direct costAntiepileptic drugs163 (63.2%)3.2 (5.4)2.019.8%Medical consultation44 (17.1%)3.0 (5.0)0.55.0%Hospitalization11 (4.3%)8.8 (11.3)0.44.0%Paraclinical investigations0 (0%)000%Transportation30 (11.6%)2.8 (4.8)0.33.0%Traditional medicine126 (48.8%)14.2 (23.8)6.968.2%Total weighted mean direct cost10.1100.0%[^1][^2]Fig. 1Distribution of epilepsy-related expenditure in Ituri, DRC.Fig. 1

3.3. Indirect Cost of Epilepsy {#s0075}
------------------------------

When considering all 258 PWE and their 244 caretakers in the households, the total number of work days lost due to epilepsy was 2790.2 days/month giving an average of 5.6 days lost per person per month. PWE lost more days compared with caretakers (mean number of days lost: 7.4 days vs 3.9 days; unpaired *t*-test: p \< 0.0001). Given that the Gross Domestic Product (GDP) of DRC in 2017 was 37.241 billion American dollars (USD) for a total population of 81,339,988 persons [@bb0085], the GDP per capita was calculated as 457.8 USD and the GDP per capita per day was 1.25 USD. Using this unit of conversion, the weighted mean indirect cost due to epilepsy was 10.0 USD per PWE monthly ([Table 2](#t0010){ref-type="table"}). Although children are considered not to actively contribute to the family income because they do not work, in the event of seizures, they prevent their adult parents/guardians from working as well. The resulting economic impact is included in the 28.0% of indirect cost due to the days of work lost by the caretaker ([Table 2](#t0010){ref-type="table"}). The weighted median indirect cost was 4.6 USD per month.Table 2Monthly indirect costs of epilepsy.Table 2ItemNumber of persons affected (%)Number of days of work lost: mean (SD)Cost in USDWeighted mean cost (USD)Percentage of indirect costIndirect cost incurred by PWE199/258 (77.1%)7.4 (8.4)9.37.272.0%Indirect cost incurred by caretaker or family138/244 (56.6%)3.9 (5.8)4.92.828.0%Total weighted mean indirect cost10.0100.0%[^3][^4]

3.4. Total Cost of Epilepsy {#s0080}
---------------------------

Summing up the weighted means of the direct and indirect costs of epilepsy, we obtained a monthly total epilepsy cost of 20.1 USD (50.2% direct cost, 49.8% indirect cost). This corresponds to an annual cost of 241.2 USD per PWE. Considering the median duration of epilepsy in this community to be 8 years, the estimated cumulative cost incurred due to epilepsy amounted to 1929.6 USD per PWE. With a prevalence of 4.6% and a total population of 255,485 in the Logo Health zone, we estimate 11,752 PWE in this area corresponding to an economic burden of 2,834,582.4 USD annually. [Table 3](#t0015){ref-type="table"} shows a comparison of epilepsy cost as reported in our study with findings in other developing countries.Table 3Annual costs of epilepsy in developing countries.Table 3Country/year of studySettings and methodsAnnual direct cost (I\$[a](#tf0005){ref-type="table-fn"})Annual indirect cost (I\$[a](#tf0005){ref-type="table-fn"})Annual total cost (I\$[a](#tf0005){ref-type="table-fn"})India, 1998 [@bb0020]−Consecutive recruitment in epilepsy centres−Direct cost: consultation, hospitalization, travel, investigations, AED cost−Indirect cost: days lost due to seizure, days lost due to travel580.71563.92144.6Burundi, 2001 [@bb0025]−Case-control study evaluating cost of care for PWE vs persons without epilepsy−Recruitment in a private hospital−Direct cost: consultation, admission and complementary exams, AED cost−Indirect cost: number of days of family life disrupted expressed as a multiple of the GDP per capita per day26.3[b](#tf0010){ref-type="table-fn"}134.7[b](#tf0010){ref-type="table-fn"}161.0[b](#tf0010){ref-type="table-fn"}South Africa, 2011 [@bb0030]−Community-based study with home visits to previously diagnosed PWE−Healthcare utilization and out-of-pocket expenditure for epilepsy were evaluated−Direct cost: visit to clinic/hospital, transportation, food/drinks purchased due to visit, traditional healer cost−AEDs freely available for PWE, thus no AED cost included−Indirect cost was not evaluated116.3NA116.3Nigeria, 2009 [@bb0035]−Cohort of children with epilepsy attending a tertiary hospital−Direct cost: medical consultation, AED cost, investigations, transport and hospitalizations−Indirect cost: cost of working days lost due to visits/hospitalization, wages lost due to abandonment of employment to care for PWE, wages paid to a domestic hired for home careVaried. Overall 71.8% of total mean costVaried. Overall 28.2% of total mean cost1819.6 (median)DRC, 2017 (this study)−Cross-sectional study evaluating cost of care of PWE on families−Recruitment in government health centres−Direct cost: consultation, hospitalization, complementary exams, AED cost, traditional medicine cost, and transportation−Indirect cost: number of days of work lost by PWE and caretaker, expressed as a multiple of the GDP per capita per day343.6340.2683.8[^5][^6]

The tornado diagram in [Fig. 2](#f0010){ref-type="fig"} shows a non-parametric one-way sensitivity analysis of the different elements contributing to epilepsy cost, using the weighted median costs as baseline for each parameter. In this diagram, the extent of variation for the different epilepsy-related costs (using the 25th and 75th percentiles) are shown, as well as their possible deviations from the total weighted median cost of 8.4 USD reported in our study population. We observed that indirect costs and traditional medicine costs had the widest margins of variation, with a tendency to overestimate.Fig. 2Tornado diagram for the cost of epilepsy per PWE in Ituri. The horizontal axis represents the monthly weighted median cost of epilepsy per PWE, for different cost inputs. The central baseline value is 8.4 USD, corresponding to the total weighted median cost per month. The values beside the horizontal bars represent the variation in cost if the 25th percentile (green: decrease from median cost) or 75th percentile (red: increase from median cost) are used as input parameters. Indirect costs in bold. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2

The mean monetary income per month in the study households was 21.7 ± 27.6 USD (median = 13.9 USD; IQR: 8.0--27.8). The monetary expenses (direct costs) due to epilepsy represented 46.5% of the household income; in addition, the total economic cost of epilepsy amounted to 52.7% of the GDP per capita ([Fig. 3](#f0015){ref-type="fig"}). The annual cost of providing recommended epilepsy care to one PWE in rural DRC was estimated at 58.0 USD in the first year and 7.0 USD per year subsequently, much lower than the reported epilepsy expenditure in our study (see Supplementary appendix 2).Fig. 3Comparison between annual household income, GDP per capita and epilepsy cost in rural Ituri.Fig. 3

4. Discussion {#s0085}
=============

To the best of our knowledge, this is the first study investigating the economic cost of epilepsy in onchocerciasis-endemic communities in the DRC. Although our one-way sensitivity analysis showed a tendency to overestimate, we were able to provide the approximate costs incurred by a family due to epilepsy, and to calculate a realistic community burden of epilepsy in Ituri using weighted means. Our findings could prove useful in conducting cost-effectiveness analyses for appropriate interventions such as AED provision and ivermectin mass drug administration in affected communities, more so as we show that providing recommended epilepsy care in these remote villages would be less costly than the reported epilepsy expenditures.

The cost of managing a PWE in rural Ituri amounted to almost half of the household income. This leaves the family with very little for monthly subsistence, and therefore results in a vicious circle of poverty. Compared to other developing countries, the annual epilepsy cost in DRC was lower than that reported in Nigeria and India, but still higher than findings from South Africa and Burundi. Possible reasons for this discrepancy include the fact that in South Africa, AED expenditure was zero (provided for free) and indirect costs were not reported; while in Burundi, cost due to traditional medicine was not taken into account ([Table 3](#t0015){ref-type="table"}). The differences in methodological approaches when conducting cost-of-illness studies [@bb0090] must also be taken into account when comparing epilepsy cost between countries. Although our data was obtained from declarations of the PWE and families which are subject to recall bias, we consider it to be fairly accurate because the chronic nature of epilepsy warrants habitual expenses which are usually well calculated and known in advance by the household. In fact, a previous study on epilepsy cost in India noted a good concordance between the cost reported by the patient and the cost computed as per the hospital prescriptions [@bb0020].

The bulk of the direct epilepsy cost went into traditional medicine. The high demand for traditional healers despite their exorbitant cost may seem paradoxical, but can be explained by their proximity to the population and their flexible payment modalities which range from cash, kind, labour or even credit/differed payments [@bb0095]. Also, the population is strongly rooted in cultural beliefs that epilepsy is mystical and prefers to take their PWE to traditional healers whom they believe have the power to solve their problem unlike modern medicine [@bb0070], [@bb0100]. Notwithstanding, the practise of traditional medicine has been shown to be detrimental to PWE, as this delays medical treatment and increases the risk of refractory scenarios upon initiation of AEDs [@bb0100]. In addition, despite the high cost of traditional treatment, it was not observed to yield superior clinical outcomes. It should therefore be discouraged among PWE, and medical services be made more available, affordable and attractive for the local population. It is expected that the cost due to traditional medicine should reduce if subsidized AEDs and epilepsy education are provided.

Expenditures on AED purchase were also important, constituting the second highest contributor to the direct cost. This finding concurs with data from other developing countries where AEDs constitute a major expenditure in epilepsy management [@bb0020], [@bb0025], [@bb0035]. In addition to being expensive for the local population, AEDs are not always available resulting in poor adherence to treatment [@bb0105]. Poor AED adherence can result in increased seizure frequency, increased cost for managing comorbidities, less productivity, greater social impact on the PWE and ultimately a multiplied economic burden from all fronts (direct, indirect and intangible costs). Indeed, epilepsy cost was shown to vary significantly depending on the severity of the condition and the response to treatment [@bb0110]. Therefore, an intervention aimed at increasing access to AEDs will have ripple effects on the overall economic cost of epilepsy. In our study, PWE spent on average 24 USD annually on AED because the drug was often unavailable at the health centres. Meanwhile, annual treatment with phenobarbital can be obtained for as low as 1 USD per year in the DRC [@bb0010], provided appropriate policies are adopted by the stakeholders to ensure routine availability of the drug at affordable prices.

The indirect cost of epilepsy calculated on the basis of days lost by the PWE and/or caretaker due to seizures was 10.0 USD per month. This was however expected to vary depending on seizure control, because PWE with less seizures are likely to be more productive resulting in reduced indirect cost. Indirect cost constituted only 49.8% of the total epilepsy cost in our study population in contrast with findings from other developing countries [@bb0020], [@bb0025] as well as developed countries, where indirect costs are usually higher due to sick leaves [@bb0115]. The main reason accounting for this difference is the frequent resort to expensive traditional healers by our study participants which inflates the direct cost. Indirect costs further reduce the family\'s purchasing power thus narrowing the chances of buying AEDs. This cycle ultimately results in more poverty and catastrophic health outcomes.

The cumulative economic cost of epilepsy and the financial burden it constitutes for the community were high. This cost could be greatly reduced if early diagnosis of epilepsy and early seizure control are achieved. Therefore, a community-based framework for epilepsy management adapted for these rural settings is needed to fill this gap in epilepsy care [@bb0120]. In addition, for onchocerciasis-endemic areas like our study site where most cases of epilepsy are due to OAE, strengthening onchocerciasis control programs will reduce the incidence of epilepsy in the community [@bb0125]. This would save the community 241.2 USD per prevented new epilepsy case every year.

This study had some limitations: Our findings are far from being exhaustive because many items that contribute to direct cost were not taken into account, such as the extra home care expenses for PWE. Due to the incomplete nature of the data collected on traditional medicine cost, we were unable to perform sensitivity analyses on the in-kind payments for traditional treatment. Also, the management of epilepsy-related complications was not included in the analyses. Although GDP per capita had been used by other authors to estimate individual living standards [@bb0025], this approach may not be ideal in our case because of the much lower economic status in rural villages compared to urban settings, and the scarcity of data to calculate GDP reliably in the DRC. Furthermore, the cross-sectional design of our study did not permit us to account for potential future costs such as unemployment resulting from early school dropout, or denied professional opportunities due to epilepsy. Finally, the socio-economic background, patient history and remission with treatment vary greatly among PWE and this influences cost at the individual level.

5. Conclusion {#s0090}
=============

The economic cost of epilepsy constitutes a major burden for PWE and their families in rural Ituri. Besides consulting traditional healers, most of the direct cost was attributed to the purchase of AEDs. Therefore, strategies to ensure regular access to affordable AEDs will not only cut down direct cost, but will ensure better health outcomes hence reducing indirect and intangible costs as well. Improved onchocerciasis control will also prevent new cases of OAE thus reducing community cost for epilepsy. In addition, community education is needed to reduce stigma and limit consultation of traditional healers, as this practice substantially increases costs but without a corresponding improvement in the quality of life of PWE.
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[^1]: Weighted median direct cost of epilepsy: \[(0.632 ∗ 1.4) + (0.171 ∗ 0.2) + (0.043 ∗ 0.5) + (0.116 ∗ 1.4) + (0.488 ∗ 5.6)\] = 3.8 USD.

[^2]: PWE: Person(s) with epilepsy; SD: Standard deviation; USD: American dollar.

[^3]: Weighted median indirect cost of epilepsy: \[(0.771 ∗ 5) + (0.566 ∗ 1.3)\] = 4.6 USD.

[^4]: PWE: Person(s) with epilepsy; SD: Standard deviation; USD: American dollar.

[^5]: I\$: 2016 International dollars.

[^6]: Only PWE treated with AED.
